Schuhmacher-Wolz U, Dieter HH, Klein D, Schneider K. Oral exposure to inorganic arsenic: evaluation of its carcinogenic and non-carcinogenic effects. Crit Rev Toxicol. 2009;39(4):271–98.
Chiu HF, Ho SC, Yang CY. Lung cancer mortality reduction after installation of tap-water supply system in an arseniasis-endemic area in southwestern Taiwan. Lung Cancer. 2004;46(3):265–70.
Rodríguez-Lado L, Sun G, Berg M, Zhang Q, Xue H, Zheng Q, et al. Groundwater arsenic contamination throughout China. Science. 2013;341(6148):866–8. https://doi.org/10.1126/science.1237484.
Chen CJ, Chuang YC, Lin TM, Wu HY. Malignant neoplasms among residents of a Blackfoot disease-endemic area in Taiwan: high-arsenic artesian well water and cancers. Cancer Res. 1985;45(11 Pt 2):5895–9.
Putila JJ, Guo NL. Association of arsenic exposure with lung cancer incidence rates in the United States. PLoS One. 2011;6(10):e25886. https://doi.org/10.1371/journal.pone.0025886.
D'Ippoliti D, Santelli E, De Sario M, Scortichini M, Davoli M, Michelozzi P. Arsenic in drinking water and mortality for cancer and chronic diseases in Central Italy, 1990-2010. PLoS One. 2015;10(9):e0138182.
Ferreccio C, González C, Milosavjlevic V, Marshall G, Sancha AM, Smith AH. Lung cancer and arsenic concentrations in drinking water in Chile. Epidemiology. 2000;11(6):673–9.
Roh T, Steinmaus C, Marshall G, Ferreccio C, Liaw J, Smith AH. Age at exposure to arsenic in water and mortality 30-40 years after exposure cessation. Am J Epidemiol. 2018;187(11):2297–305. https://doi.org/10.1093/aje/kwy159.
Smith AH, Marshall G, Roh T, Ferreccio C, Liaw J, Steinmaus C. Lung, bladder, and kidney cancer mortality 40 years after arsenic exposure reduction. J Natl Cancer Inst. 2018;110(3):241–9. https://doi.org/10.1093/jnci/djx201.
Mendez WM Jr, Eftim S, Cohen J, Warren I, Cowden J, Lee JS, et al. Relationships between arsenic concentrations in drinking water and lung and bladder cancer incidence in U.S. counties. J Expo Sci Environ Epidemiol. 2017;27(3):235–43. https://doi.org/10.1038/jes.2016.58.
Ahmad A, van der Wens P, Baken K, de Waal L, Bhattacharya P, Stuyfzand P. Arsenic reduction to <1microg/L in Dutch drinking water. Environ Int. 2020;134:105253. https://doi.org/10.1016/j.envint.2019.105253.
Ferdosi H, Dissen EK, Afari-Dwamena NA, Li J, Chen R, Feinleib M, et al. Arsenic in drinking water and lung cancer mortality in the United States: An analysis based on US counties and 30 years of observation (1950-1979). J Environ Public Health. 2016;2016:1602929.
George CM, Brooks WA, Graziano JH, Nonyane BA, Hossain L, Goswami D, et al. Arsenic exposure is associated with pediatric pneumonia in rural Bangladesh: a case control study. Environ Health. 2015;14(1):83. https://doi.org/10.1186/s12940-015-0069-9.
Bhattacharyya P, Sen P, Ghosh A, Saha C, Bhattacharya PP, Das A, et al. Chronic lung disease and detection of pulmonary artery dilatation in high resolution computerized tomography of chest in chronic arsenic exposure. J Environ Sci Health A Tox Hazard Subst Environ Eng. 2014;49(13):1453–61.
Siddique AE, Rahman M, Hossain MI, Karim Y, Hasibuzzaman MM, Biswas S, et al. Association between chronic arsenic exposure and the characteristic features of asthma. Chemosphere. 2020;246:125790.
Yang MH, Chang KJ, Li B, Chen WS. Arsenic trioxide suppresses tumor growth through Antiangiogenesis via Notch signaling blockade in small-cell lung cancer. Biomed Res Int. 2019;2019:4647252.
Wang L, Hu X, Xu Y, Liu Z. Arsenic trioxide inhibits lung metastasis of mouse colon cancer via reducing the infiltration of regulatory T cells. Tumour Biol. 2016;37(11):15165–73. https://doi.org/10.1007/s13277-016-5377-3.
Platzbecker U, Avvisati G, Cicconi L, Thiede C, Paoloni F, Vignetti M, Ferrara F, Divona M, Albano F, Efficace F, et al. Improved outcomes with retinoic acid and arsenic trioxide compared with retinoic acid and chemotherapy in non-high-risk acute Promyelocytic leukemia: final results of the randomized Italian-German APL0406 trial. J Clin Oncol. 2017;35(6):605–612. https://doi.org/10.1200/JCO.2016.67.1982.
Burnett AK, Russell NH, Hills RK, Bowen D, Kell J, Knapper S, et al. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial. Lancet Oncol. 2015;16(13):1295–305. https://doi.org/10.1016/S1470-2045(15)00193-X.
Lallemand-Breitenbach V, Zhu J, Chen Z, de Thé H. Curing APL through PML/RARA degradation by As2O3. Trends Mol Med. 2012;18(1):36–42. https://doi.org/10.1016/j.molmed.2011.10.001.
Röllig C, Illmer T. The efficacy of arsenic trioxide for the treatment of relapsed and refractory multiple myeloma: a systematic review. Cancer Treat Rev. 2009;35(5):425–30. https://doi.org/10.1016/j.ctrv.2009.04.007.
List A, Beran M, DiPersio J, Slack J, Vey N, Rosenfeld C, et al. Opportunities for Trisenox (arsenic trioxide) in the treatment of myelodysplastic syndromes. Leukemia. 2003;17(8):1499–507. https://doi.org/10.1038/sj.leu.2403021.
Murgo A. Clinical trials of arsenic trioxide in hematologic and solid tumors: overview of the National Cancer Institute cooperative Research and Development studies. Oncologist. 2001;6(S2):22–8. https://doi.org/10.1634/theoncologist.6-suppl_2-22.
Celik I, Gallicchio L, Boyd K, Lam TK, Matanoski G, Tao X, et al. Arsenic in drinking water and lung cancer: a systematic review. Environ Res. 2008;108(1):48–55.
Chen C, Hsu L, Chiou H, Hsueh Y, Chen S, Wu M, et al. Ingested arsenic, cigarette smoking, and lung cancer risk: a follow-up study in arseniasis-endemic areas in Taiwan. JAMA. 2004;292(24):2984–90.
Bardach A, Ciapponi A, Soto N, Chaparro M, Calderon M, Briatore A, et al. Epidemiology of chronic disease related to arsenic in Argentina: a systematic review. Sci Total Environ. 2015;538:802–16. https://doi.org/10.1016/j.scitotenv.2015.08.070.
Krug H. A study on arsenic lung cancer. Z Gesamte Inn Med. 1959;14(9):426–31.
Satterlee HS. The arsenic-poisoning epidemic of 1900. Its relation to lung cancer in 1960 - an exercise in retrospective epidemiology. N Engl J Med. 1960;263:676–84.
Galy P, Touraine R, Brune J, Roudier P, Gallois P. Pulmonary cancer of arsenical origin in Beaujolais vineyeard workers. J Fr Med Chir Thorac. 1963;17:303–11.
Pinto SS, Nelson KW. Arsenic toxicology and industrial exposure. Annu Rev Pharmacol Toxicol. 1976;16:95–100.
Pershagen G. The carcinogenicity of arsenic. Environ Health Perspect. 1981;40:93–100.
Marshall G, Ferreccio C, Yuan Y, Bates M, Steinmaus C, Selvin S, et al. Fifty-year study of lung and bladder cancer mortality in Chile related to arsenic in drinking water. J Natl Cancer Inst. 2007;99(12):920–8.
Chiou H, Hsueh Y, Liaw K, Horng S, Chiang M, Pu Y, et al. Incidence of internal cancers and ingested inorganic arsenic: a seven-year follow-up study in Taiwan. Cancer Res. 1995;55(6):1296–300.
Smith A, Marshall G, Roh T, Ferreccio C, Liaw J, Steinmaus C. Lung, bladder, and kidney cancer mortality 40 years after arsenic exposure reduction. J Natl Cancer Inst. 2018;110(3):241–9. https://doi.org/10.1093/jnci/djx201.
Cheng P, Weng S, Chiang C, Lai F. Relationship between arsenic-containing drinking water and skin cancers in the arseniasis endemic areas in Taiwan. J Dermatol. 2016;43(2):181–6.
Tsai S, Wang T, Ko Y. Cancer mortality trends in a Blackfoot disease endemic community of Taiwan following water source replacement. Journal of toxicology and environmental health Part A. 1998;55(6):389–404. https://doi.org/10.1080/009841098158322.
García-Esquinas E, Pollán M, Umans JG, Francesconi KA, Goessler W, Guallar E, et al. Arsenic exposure and cancer mortality in a US-based prospective cohort: the strong heart study. Cancer Epidemiol Biomark Prev. 2013;22(11):1944–53.
Zhang H, Wang L, Wang Y, Chang S. Using disability-adjusted life years to estimate the cancer risks of low-level arsenic in drinking water. J Environ Sci Health A Tox Hazard Subst Environ Eng. 2020;55(1):63–70.
Steinmaus CM, Ferreccio C, Romo JA, Yuan Y, Cortes S, Marshall G, et al. Drinking water arsenic in northern Chile: high cancer risks 40 years after exposure cessation. Cancer Epidemiol Biomark Prev. 2013;22(4):623–30.
Dauphiné DC, Smith AH, Yuan Y, Balmes JR, Bates MN, Steinmaus C. Case-control study of arsenic in drinking water and lung cancer in California and Nevada. Int J Environ Res Public Health. 2013;10(8):3310–24. https://doi.org/10.3390/ijerph10083310.
Chen CL, Chiou HY, Hsu LI, Hsueh YM, Wu MM, Chen CJ. Ingested arsenic, characteristics of well water consumption and risk of different histological types of lung cancer in northeastern Taiwan. Environ Res. 2010;110(5):455–62.
Mostafa MG, McDonald JC, Cherry NM. Lung cancer and exposure to arsenic in rural Bangladesh. Occup Environ Med. 2008;65(11):765–8. https://doi.org/10.1136/oem.2007.037895.
Zhang H, Chang S, Wang L, Wang W. Estimating and comparing the cancer risks from THMs and low-level arsenic in drinking water based on disability-adjusted life years. Water Res. 2018;145:83–93. https://doi.org/10.1016/j.watres.2018.08.012.
Parvez F, Chen Y, Yunus M, Olopade C, Segers S, Slavkovich V, et al. Arsenic exposure and impaired lung function. Findings from a large population-based prospective cohort study. Am J Respir Crit Care Med. 2013;188(7):813–9. https://doi.org/10.1164/rccm.201212-2282OC.
De BK, Majumdar D, Sen S, Guru S, Kundu S. Pulmonary involvement in chronic arsenic poisoning from drinking contaminated ground-water. J Assoc Physicians India. 2004;52:395–400.
Guha Mazumder DN. Arsenic and non-malignant lung disease. J Environ Sci Health A Tox Hazard Subst Environ Eng. 2007;42(12):1859–67.
Smith AH, Marshall G, Yuan Y, Ferreccio C, Liaw J, von Ehrenstein O, et al. Increased mortality from lung cancer and bronchiectasis in young adults after exposure to arsenic in utero and in early childhood. Environ Health Perspect. 2006;114(8):1293–6. https://doi.org/10.1289/ehp.8832.
Waalkes M, Qu W, Tokar E, Kissling G, Dixon D. Lung tumors in mice induced by "whole-life" inorganic arsenic exposure at human-relevant doses. Arch Toxicol. 2014;88(8):1619–29.
Wang Z, Zhao Y, Smith E, Goodall GJ, Drew PA, Brabletz T, et al. Reversal and prevention of arsenic-induced human bronchial epithelial cell malignant transformation by microRNA-200b. Toxicol Sci. 2011;121(1):110–22. https://doi.org/10.1093/toxsci/kfr029.
Wang M, Ge X, Zheng J, Li D, Liu X, Wang L, et al. Role and mechanism of miR-222 in arsenic-transformed cells for inducing tumor growth. Oncotarget. 2016;7(14):17805–14. https://doi.org/10.18632/oncotarget.7525.
He J, Wang M, Jiang Y, Chen Q, Xu S, Xu Q, et al. Chronic arsenic exposure and angiogenesis in human bronchial epithelial cells via the ROS/miR-199a-5p/HIF-1α/COX-2 pathway. Environ Health Perspect. 2014;122(3):255–61. https://doi.org/10.1289/ehp.1307545.
Xu W, Luo F, Sun B, Ye H, Li J, Shi L, et al. HIF-2alpha, acting via miR-191, is involved in angiogenesis and metastasis of arsenite-transformed HBE cells. Toxicol Res (Camb). 2016;5(1):66–78. https://doi.org/10.1039/C5TX00225G.
Zhong M, Huang Z, Wang L, Lin Z, Cao Z, Li X, et al. Malignant transformation of human bronchial epithelial cells induced by arsenic through STAT3/miR-301a/SMAD4 loop. Sci Rep. 2018;8(1):13291. https://doi.org/10.1038/s41598-018-31516-0.
Chen QY, Li J, Sun H, Wu F, Zhu Y, Kluz T, et al. Role of miR-31 and SATB2 in arsenic-induced malignant BEAS-2B cell transformation. Mol Carcinog. 2018;57(8):968–77.
Chen C, Jiang X, Gu S, Zhang Z. MicroRNA-155 regulates arsenite-induced malignant transformation by targeting Nrf2-mediated oxidative damage in human bronchial epithelial cells. Toxicol Lett. 2017;278:38–47. https://doi.org/10.1016/j.toxlet.2017.07.215.
Ling M, Li Y, Xu Y, Pang Y, Shen L, Jiang R, et al. Regulation of miRNA-21 by reactive oxygen species-activated ERK/NF-kappaB in arsenite-induced cell transformation. Free Radic Biol Med. 2012;52(9):1508–18.
Pratheeshkumar P, Son YO, Divya SP, Wang L, Zhang Z, Shi X. Oncogenic transformation of human lung bronchial epithelial cells induced by arsenic involves ROS-dependent activation of STAT3-miR-21-PDCD4 mechanism. Sci Rep. 2016;6:37227.
Luo F, Ji J, Liu Y, Xu Y, Zheng G, Jing J, et al. MicroRNA-21, up-regulated by arsenite, directs the epithelial-mesenchymal transition and enhances the invasive potential of transformed human bronchial epithelial cells by targeting PDCD4. Toxicol Lett. 2015;232(1):301–9. https://doi.org/10.1016/j.toxlet.2014.11.001.
Gentry PR, McDonald TB, Sullivan DE, Shipp AM, Yager JW, Clewell HJ 3rd. Analysis of genomic dose-response information on arsenic to inform key events in a mode of action for carcinogenicity. Environ Mol Mutagen. 2010;51(1):1–14. https://doi.org/10.1002/em.20505.
Miao Z, Wu L, Lu M, Meng X, Gao B, Qiao X, et al. Analysis of the transcriptional regulation of cancer-related genes by aberrant DNA methylation of the cis-regulation sites in the promoter region during hepatocyte carcinogenesis caused by arsenic. Oncotarget. 2015;6(25):21493–506. https://doi.org/10.18632/oncotarget.4085.
Costa M. Review of arsenic toxicity, speciation and polyadenylation of canonical histones. Toxicol Appl Pharmacol. 2019;375:1–4. https://doi.org/10.1016/j.taap.2019.05.006.
Lee CH, Wu SB, Hong CH, Chen GS, Wei YH, Yu HS. Involvement of mtDNA damage elicited by oxidative stress in the arsenical skin cancers. J Invest Dermatol. 2013;133(7):1890–900.
Haque R, Chaudhary A, Sadaf N. Immunomodulatory role of arsenic in regulatory T cells. Endocr Metab Immune Disord Drug Targets. 2017;17(3):176–81. https://doi.org/10.2174/1871530317666170818114454.
Ramsey KA, Foong RE, Sly PD, Larcombe AN, Zosky GR. Early life arsenic exposure and acute and long-term responses to influenza a infection in mice. Environ Health Perspect. 2013;121(10):1187–93. https://doi.org/10.1289/ehp.1306748.
Henderson MW, Madenspacher JH, Whitehead GS, Thomas SY, Aloor JJ, Gowdy KM, et al. Effects of orally ingested arsenic on respiratory epithelial permeability to bacteria and small molecules in mice. Environ Health Perspect. 2017;125(9):097024.
Ramsey KA, Bosco A, McKenna KL, Carter KW, Elliot JG, Berry LJ, et al. In utero exposure to arsenic alters lung development and genes related to immune and mucociliary function in mice. Environ Health Perspect. 2013;121(2):244–50. https://doi.org/10.1289/ehp.1205590.
Li Y, Shen L, Xu H, Pang Y, Xu Y, Ling M, et al. Up-regulation of cyclin D1 by JNK1/c-Jun is involved in tumorigenesis of human embryo lung fibroblast cells induced by a low concentration of arsenite. Toxicol Lett. 2011;206(2):113–20. https://doi.org/10.1016/j.toxlet.2011.06.024.
Wang F, Shi Y, Yadav S, Wang H. p52-Bcl3 complex promotes cyclin D1 expression in BEAS-2B cells in response to low concentration arsenite. Toxicology. 2010;273(1-3):12–8. https://doi.org/10.1016/j.tox.2010.04.009.
Zhang Z, Pratheeshkumar P, Budhraja A, Son YO, Kim D, Shi X. Role of reactive oxygen species in arsenic-induced transformation of human lung bronchial epithelial (BEAS-2B) cells. Biochem Biophys Res Commun. 2015;456(2):643–8. https://doi.org/10.1016/j.bbrc.2014.12.010.
Son YO, Pratheeshkumar P, Roy RV, Hitron JA, Wang L, Divya SP, et al. Antioncogenic and oncogenic properties of Nrf2 in arsenic-induced carcinogenesis. J Biol Chem. 2015;290(45):27090–100.
Qi Y, Zhang M, Li H, Frank JA, Dai L, Liu H, et al. Autophagy inhibition by sustained overproduction of IL6 contributes to arsenic carcinogenesis. Cancer Res. 2014;74(14):3740–52.
Liu LZ, Jiang Y, Carpenter RL, Jing Y, Peiper SC, Jiang BH. Role and mechanism of arsenic in regulating angiogenesis. PLoS One. 2011;6(6):e20858.
Zhao F, Malm SW, Hinchman AN, Li H, Beeks CG, Klimecki WT. Arsenite-induced pseudo-hypoxia results in loss of anchorage-dependent growth in BEAS-2B pulmonary epithelial cells. PLoS One. 2014;9(12):e114549. https://doi.org/10.1371/journal.pone.0114549.
Xu Y, Zhao Y, Xu W, Luo F, Wang B, Li Y, et al. Involvement of HIF-2alpha-mediated inflammation in arsenite-induced transformation of human bronchial epithelial cells. Toxicol Appl Pharmacol. 2013;272(2):542–50. https://doi.org/10.1016/j.taap.2013.06.017.
Xu Y, Li Y, Pang Y, Ling M, Shen L, Yang X, et al. EMT and stem cell-like properties associated with HIF-2alpha are involved in arsenite-induced transformation of human bronchial epithelial cells. PLoS One. 2012;7(5):e37765.
Xu Y, Li Y, Pang Y, Ling M, Shen L, Jiang R, et al. Blockade of p53 by HIF-2alpha, but not HIF-1alpha, is involved in arsenite-induced malignant transformation of human bronchial epithelial cells. Arch Toxicol. 2012;86(6):947–59. https://doi.org/10.1007/s00204-012-0810-x.
Chiang H, Tsou T. Arsenite enhances the benzo[a]pyrene diol epoxide (BPDE)-induced mutagenesis with no marked effect on repair of BPDE-DNA adducts in human lung cells. Toxicol in Vitro. 2009;23(5):897–905. https://doi.org/10.1016/j.tiv.2009.05.009.
Liu X, Sun B, Wang X, Nie J, Chen Z, An Y, et al. Synergistic effect of radon and sodium arsenite on DNA damage in HBE cells. Environ Toxicol Pharmacol. 2016;41:127–31. https://doi.org/10.1016/j.etap.2015.11.013.
Rossman T, Uddin A, Burns F, Bosland M. Arsenite is a cocarcinogen with solar ultraviolet radiation for mouse skin: an animal model for arsenic carcinogenesis. Toxicol Appl Pharmacol. 2001;176(1):64–71. https://doi.org/10.1006/taap.2001.9277.
Ebert F, Weiss A, Bultemeyer M, Hamann I, Hartwig A, Schwerdtle T. Arsenicals affect base excision repair by several mechanisms. Mutat Res. 2011;715(1-2):32–41. https://doi.org/10.1016/j.mrfmmm.2011.07.004.
Muenyi CS, Ljungman M, States JC. Arsenic disruption of DNA damage responses-potential role in carcinogenesis and chemotherapy. Biomolecules. 2015;5(4):2184–93.
Cui X, Wakai T, Shirai Y, Hatakeyama K, Hirano S. Chronic oral exposure to inorganic arsenate interferes with methylation status of p16INK4a and RASSF1A and induces lung cancer in a/J mice. Toxicol Sci. 2006;91(2):372–81. https://doi.org/10.1093/toxsci/kfj159.
Boellmann F, Zhang L, Clewell H, Schroth G, Kenyon E, Andersen M, et al. Genome-wide analysis of DNA methylation and gene expression changes in the mouse lung following subchronic arsenate exposure. Toxicol Sci. 2010;117(2):404–17.
Li M, Cai J, Chiu J. Arsenic induces oxidative stress and activates stress gene expressions in cultured lung epithelial cells. J Cell Biochem. 2002;87(1):29–38.
Sherwood CL, Lantz RC, Boitano S. Chronic arsenic exposure in nanomolar concentrations compromises wound response and intercellular signaling in airway epithelial cells. Toxicol Sci. 2013;132(1):222–34. https://doi.org/10.1093/toxsci/kfs331.
Sherwood CL, Liguori AE, Olsen CE, Lantz RC, Burgess JL, Boitano S. Arsenic compromises conducting airway epithelial barrier properties in primary mouse and immortalized human cell cultures. PLoS One. 2013;8(12):e82970.
Zhao Y, Su X, Gao Y, Yin H, Wang L, Qiao R, et al. Exposure of low-concentration arsenic-initiated inflammation and autophagy in rat lungs. J Biochem Mol Toxicol. 2019;33(7):e22334. https://doi.org/10.1002/jbt.22334.
Tsou T, Yeh S, Tsai E, Tsai F, Chao H, Chang L. Arsenite enhances tumor necrosis factor-alpha-induced expression of vascular cell adhesion molecule-1. Toxicol Appl Pharmacol. 2005;209(1):10–8.
Kitchin K. Recent advances in arsenic carcinogenesis: modes of action, animal model systems, and methylated arsenic metabolites. Toxicol Appl Pharmacol. 2001;172(3):249–61.
Yang H, Chou H, Han B, Huang S. Lifelong inorganic arsenic compounds consumption affected blood pressure in rats. Food Chem Toxicol. 2007;45(12):2479–87. https://doi.org/10.1016/j.fct.2007.05.024.
Kinoshita A, Wanibuchi H, Wei M, Yunoki T, Fukushima S. Elevation of 8-hydroxydeoxyguanosine and cell proliferation via generation of oxidative stress by organic arsenicals contributes to their carcinogenicity in the rat liver and bladder. Toxicol Appl Pharmacol. 2007;221(3):295–305. https://doi.org/10.1016/j.taap.2007.03.024.
Liu J, Benbrahim-Tallaa L, Qian X, Yu L, Xie Y, Boos J, et al. Further studies on aberrant gene expression associated with arsenic-induced malignant transformation in rat liver TRL1215 cells. Toxicol Appl Pharmacol. 2006;216(3):407–15. https://doi.org/10.1016/j.taap.2006.06.006.
Mazumder D. Effect of chronic intake of arsenic-contaminated water on liver. Toxicol Appl Pharmacol. 2005;206(2):169–75.
Liu J, Waalkes M. Liver is a target of arsenic carcinogenesis. Toxicol Sci. 2008;105(1):24–32. https://doi.org/10.1093/toxsci/kfn120.
Orr S, Bridges C. Chronic kidney disease and exposure to nephrotoxic metals. Int J Mol Sci. 2017:18(5).
Mochizuki H: Arsenic neurotoxicity in humans. Int J Mol Sci 2019, 20(14).
IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Some drinking-water disinfectants and contaminants, including arsenic. IARC monographs on the evaluation of carcinogenic risks to humans. 2004; 84:1-477.
Bozack AK, Saxena R, Gamble MV. Nutritional influences on one-carbon metabolism: effects on arsenic methylation and toxicity. Annu Rev Nutr. 2018;38:401–29.
Li J, Duan X, Dong D, Zhang Y, Zhao L, Li W, et al. Tissue-specific distributions of inorganic arsenic and its methylated metabolites, especially in cerebral cortex, cerebellum and hippocampus of mice after a single oral administration of arsenite. J Trace Elem Med Biol. 2017;43:15–22. https://doi.org/10.1016/j.jtemb.2016.10.002.
Kenyon EM, Hughes MF, Adair BM, Highfill JH, Crecelius EA, Clewell HJ, et al. Tissue distribution and urinary excretion of inorganic arsenic and its methylated metabolites in C57BL6 mice following subchronic exposure to arsenate in drinking water. Toxicol Appl Pharmacol. 2008;232(3):448–55.
Hughes MF, Kenyon EM, Edwards BC, Mitchell CT, Razo LM, Thomas DJ. Accumulation and metabolism of arsenic in mice after repeated oral administration of arsenate. Toxicol Appl Pharmacol. 2003;191(3):202–10.
Naranmandura H, Chen X, Tanaka M, Wang WW, Rehman K, Xu S, et al. Release of apoptotic cytochrome C from mitochondria by dimethylarsinous acid occurs through interaction with voltage-dependent anion channel in vitro. Toxicol Sci. 2012;128(1):137–46.
Kligerman AD, Doerr CL, Tennant AH, Harrington-Brock K, Allen JW, Winkfield E, et al. Methylated trivalent arsenicals as candidate ultimate genotoxic forms of arsenic: induction of chromosomal mutations but not gene mutations. Environ Mol Mutagen. 2003;42(3):192–205. https://doi.org/10.1002/em.10192.
Naranmandura H, Xu S, Koike S, Pan LQ, Chen B, Wang YW, et al. The endoplasmic reticulum is a target organelle for trivalent dimethylarsinic acid (DMAIII)-induced cytotoxicity. Toxicol Appl Pharmacol. 2012;260(3):241–9. https://doi.org/10.1016/j.taap.2012.02.017.
Yamanaka K, Kato K, Mizoi M, An Y, Takabayashi F, Nakano M, et al. The role of active arsenic species produced by metabolic reduction of dimethylarsinic acid in genotoxicity and tumorigenesis. Toxicol Appl Pharmacol. 2004;198(3):385–93.
Notch EG, Goodale BC, Barnaby R, Coutermarsh B, Berwin B, Taylor VF, et al. Monomethylarsonous acid (MMAIII) has an adverse effect on the innate immune response of human bronchial epithelial cells to Pseudomonas aeruginosa. PLoS One. 2015;10(11):e0142392. https://doi.org/10.1371/journal.pone.0142392.
de Thé H, Chen Z. Acute promyelocytic leukaemia: novel insights into the mechanisms of cure. Nat Rev Cancer. 2010;10(11):775–83. https://doi.org/10.1038/nrc2943.
Lin C, Huang Y, Cho C, Lin Y, Lo C, Kuo T, et al. Targeting positive feedback between BASP1 and EGFR as a therapeutic strategy for lung cancer progression. Theranostics. 2020;10(24):10925–39. https://doi.org/10.7150/thno.49425.
Luo F, Zhuang Y, Sides MD, Sanchez CG, Shan B, White ES, et al. Arsenic trioxide inhibits transforming growth factor-β1-induced fibroblast to myofibroblast differentiation in vitro and bleomycin induced lung fibrosis in vivo. Respir Res. 2014;15(1):51. https://doi.org/10.1186/1465-9921-15-51.
Li K, Zhang L, Xiang X, Gong S, Ma L, Xu L, et al. Arsenic trioxide alleviates airway hyperresponsiveness and promotes apoptosis of CD4+ T lymphocytes: evidence for involvement of the ER stress-CHOP pathway. Ir J Med Sci. 2013;182(4):573–83.
Zhang L, Li K, Bing Ma L, Gong SB, Wang GY, Liu Y, et al. Effects and mechanism of arsenic trioxide on reversing the asthma pathologies including Th17-IL-17 axis in a mouse model. Iran J Allergy Asthma Immunol. 2012;11(2):133–45.
Chu KH, Lee CC, Hsin SC, Cai BC, Wang JH, Chiang BL. Arsenic trioxide alleviates airway hyperresponsiveness and eosinophilia in a murine model of asthma. Cell Mol Immunol. 2010;7(5):375–80.
Leung LL, Lam SK, Li YY, Ho JC. Tumour growth-suppressive effect of arsenic trioxide in squamous cell lung carcinoma. Oncol Lett. 2017;14(3):3748–54. https://doi.org/10.3892/ol.2017.6646.
Walker AM, Stevens JJ, Ndebele K, Tchounwou PB. Evaluation of arsenic trioxide potential for lung cancer treatment: assessment of apoptotic mechanisms and oxidative damage. J Cancer Sci Ther. 2016;8(1):1–9. https://doi.org/10.4172/1948-5956.1000379.
Yang MH, Chang KJ, Zheng JC, Huang H, Sun GY, Zhao XW, et al. Anti-angiogenic effect of arsenic trioxide in lung cancer via inhibition of endothelial cell migration, proliferation and tube formation. Oncol Lett. 2017;14(3):3103–9. https://doi.org/10.3892/ol.2017.6518.
Zheng JC, Chang KJ, Jin YX, Zhao XW, Li B, Yang MH. Arsenic trioxide inhibits the metastasis of small cell lung cancer by blocking Calcineurin-nuclear factor of activated T cells (NFAT) signaling. Med Sci Monit. 2019;25:2228–37. https://doi.org/10.12659/MSM.913091.
Han YH, Kim SZ, Kim SH, Park WH. Arsenic trioxide inhibits the growth of Calu-6 cells via inducing a G2 arrest of the cell cycle and apoptosis accompanied with the depletion of GSH. Cancer Lett. 2008;270(1):40–55.
Leung L, Lam S, Li Y, Ho J. Tumour growth-suppressive effect of arsenic trioxide in squamous cell lung carcinoma. Oncol Lett. 2017;14(3):3748–54.
Lam S, Mak J, Zheng C, Li Y, Kwong Y, Ho J. Downregulation of thymidylate synthase with arsenic trioxide in lung adenocarcinoma. Int J Oncol. 2014;44(6):2093–102. https://doi.org/10.3892/ijo.2014.2364.
Zhai B, Jiang X, He C, Zhao D, Ma L, Xu L, et al. Arsenic trioxide potentiates the anti-cancer activities of sorafenib against hepatocellular carcinoma by inhibiting Akt activation. Tumour Biol. 2015;36(4):2323–34. https://doi.org/10.1007/s13277-014-2839-3.
Wahiduzzaman M, Ota A, Karnan S, Hanamura I, Mizuno S, Kanasugi J, et al. Novel combined Ato-C treatment synergistically suppresses proliferation of Bcr-Abl-positive leukemic cells in vitro and in vivo. Cancer Lett. 2018;433:117–30. https://doi.org/10.1016/j.canlet.2018.06.027.
Wu P, Liu L, Weng J, Geng S, Deng C, Lu Z, et al. The synergistic effects of Decitabine combined with arsenic trioxide (ATO) in the human myelodysplastic syndrome cell line SKM-1. Indian J Hematol Blood Transfus. 2016;32(4):412–7.
Peng X, Li W, Yuan L, Mehta RG, Kopelovich L, McCormick DL. Inhibition of proliferation and induction of autophagy by atorvastatin in PC3 prostate cancer cells correlate with downregulation of Bcl2 and upregulation of miR-182 and p21. PLoS One. 2013;8(8):e70442.
Lam S, Li Y, Zheng C, Leung L, Ho J. E2F1 downregulation by arsenic trioxide in lung adenocarcinoma. Int J Oncol. 2014;45(5):2033–43. https://doi.org/10.3892/ijo.2014.2609.
Qu G, Xiu Q, Li B, Liu Y, Zhang L. Arsenic trioxide inhibits the growth of human lung cancer cell lines via cell cycle arrest and induction of apoptosis at both normoxia and hypoxia. Toxicol Ind Health. 2009;25(8):505–15. https://doi.org/10.1177/0748233709345936.
Cheng Y, Chang L, Tsou T. Mitogen-activated protein kinases mediate arsenic-induced down-regulation of survivin in human lung adenocarcinoma cells. Arch Toxicol. 2006;80(6):310–8. https://doi.org/10.1007/s00204-005-0045-1.
Zheng CY, Lam SK, Li YY, Ho JC. Arsenic trioxide-induced cytotoxicity in small cell lung cancer via altered redox homeostasis and mitochondrial integrity. Int J Oncol. 2015;46(3):1067–78. https://doi.org/10.3892/ijo.2015.2826.
Gu SY, Chen HY, Dai HM, Li XY, Zhang ZZ. miR-155/BACH1 signaling pathway in human lung adenocarcinoma cell death induced by arsenic trioxide. Sichuan Da Xue Xue Bao Yi Xue Ban. 2017;48(6):828–33.
Yang MH, Zang YS, Huang H, Chen K, Li B, Sun GY, et al. Arsenic trioxide exerts anti-lung cancer activity by inhibiting angiogenesis. Curr Cancer Drug Targets. 2014;14(6):557–66. https://doi.org/10.2174/1568009614666140725090000.
Jiang X, Chen C, Zhao W, Zhang Z. Sodium arsenite and arsenic trioxide differently affect the oxidative stress, genotoxicity and apoptosis in A549 cells: an implication for the paradoxical mechanism. Environ Toxicol Pharmacol. 2013;36(3):891–902. https://doi.org/10.1016/j.etap.2013.08.002.
Klein CB, Leszczynska J, Hickey C, Rossman TG. Further evidence against a direct genotoxic mode of action for arsenic-induced cancer. Toxicol Appl Pharmacol. 2007;222(3):289–97.
Chen CL, Hsu LI, Chiou HY, Hsueh YM, Chen SY, Wu MM, et al. Ingested arsenic, cigarette smoking, and lung cancer risk: a follow-up study in arseniasis-endemic areas in Taiwan. JAMA. 2004;292(24):2984–90. https://doi.org/10.1001/jama.292.24.2984.
Chen H, Lee LS, Li G, Tsao SW, Chiu JF. Upregulation of glycolysis and oxidative phosphorylation in benzo[α]pyrene and arsenic-induced rat lung epithelial transformed cells. Oncotarget. 2016;7(26):40674–89. https://doi.org/10.18632/oncotarget.9814.
Gentry PR, Covington TR, Mann S, Shipp AM, Yager JW, Clewell Iii HJ. Physiologically based pharmacokinetic modeling of arsenic in the mouse. J Toxic Environ Health A. 2004;67(1):43–71. https://doi.org/10.1080/15287390490253660.
Wang Q, Jiang Y, Naranmandura H. Therapeutic strategy of arsenic trioxide in the fight against cancers and other diseases. Metallomics. 2020;12(3):326–36. https://doi.org/10.1039/C9MT00308H.
Shen Z, Shen J, Cai W, Hong C, Zheng M. The alteration of mitochondria is an early event of arsenic trioxide induced apoptosis in esophageal carcinoma cells. Int J Mol Med. 2000;5(2):155–8. https://doi.org/10.3892/ijmm.5.2.155.
Askar N, Cirpan T, Toprak E, Karabulut B, Selvi N, Terek M, et al. Arsenic trioxide exposure to ovarian carcinoma cells leads to decreased level of topoisomerase II and cytotoxicity. Int J Gynecol Cancer. 2006;16(4):1552–6. https://doi.org/10.1111/j.1525-1438.2006.00626.x.
Zheng CY, Lam SK, Li YY, Fong BM, Mak JC, Ho JC. Combination of arsenic trioxide and chemotherapy in small cell lung cancer. Lung Cancer. 2013;82(2):222–30. https://doi.org/10.1016/j.lungcan.2013.08.022.
Diepart C, Karroum O, Magat J, Feron O, Verrax J, Calderon PB, et al. Arsenic trioxide treatment decreases the oxygen consumption rate of tumor cells and radiosensitizes solid tumors. Cancer Res. 2012;72(2):482–90. https://doi.org/10.1158/0008-5472.CAN-11-1755.
Jiang TT, Brown SL, Kim JH. Combined effect of arsenic trioxide and sulindac sulfide in A549 human lung cancer cells in vitro. J Exp Clin Cancer Res. 2004;23(2):259–62.
Lam S, Leung L, Li Y, Zheng C, Ho J. Combination effects of arsenic trioxide and fibroblast growth factor receptor inhibitor in squamous cell lung carcinoma. Lung Cancer (Amsterdam, Netherlands). 2016;101:111–9.
Park H, Han B, Park W: Combination of arsenic trioxide and Valproic acid efficiently inhibits growth of lung cancer cells via G2/M-phase arrest and apoptotic cell death. Int J Mol Sci 2020, 21(7) 2649.